Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Botulinum Toxin Type A in Neurogenic Overactive Bladder
NCT00575016Phase 2Terminated
- Sponsor
- Allergan
- Start
- Dec 2007
- Primary completion
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of onabotulinumtoxinA in Neurogenic Bladder (NB), sponsored by Allergan. Started Dec 2007; status: terminated.
02
Drugs
onabotulinumtoxinA
03
Conditions
Neurogenic Bladder (NB)
Beyond the preview
Go deeper on NCT00575016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00575016.